This article is
- freely available
Trends in Personalized Therapies in Oncology: The (Venture) Capitalist’s Perspective
Index Ventures, Rue de Jargonnant 2, 1207 Geneva, Switzerland
* Author to whom correspondence should be addressed.
Received: 9 February 2012; in revised form: 22 February 2012 / Accepted: 29 February 2012 / Published: 7 March 2012
Abstract: Oncology is one of the most important fields of personalized medicine as a majority of efforts in this field have recently centered on targeted cancer drug development. New tools are continuously being developed that promise to make cancer treatment more efficacious while causing fewer side effects. Like most industries, the biopharmaceutical industry is also following certain global trends and these are analyzed in this article. As academia and industry are mutually dependent on each other, researchers in the field should be aware of those trends and the immediate consequences for their research. It is important for the future of this field that there is a healthy relationship among all interested parties as the challenges of personalized medicine are becoming ever more complex.
Keywords: global industry trends; collaboration BioPharma–Academia; oncology drug development; translational research
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Fleck, R.; Bach, D. Trends in Personalized Therapies in Oncology: The (Venture) Capitalist’s Perspective. J. Pers. Med. 2012, 2, 15-34.
Fleck R, Bach D. Trends in Personalized Therapies in Oncology: The (Venture) Capitalist’s Perspective. Journal of Personalized Medicine. 2012; 2(1):15-34.
Fleck, Roman; Bach, Daniel. 2012. "Trends in Personalized Therapies in Oncology: The (Venture) Capitalist’s Perspective." J. Pers. Med. 2, no. 1: 15-34.